{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:09:34Z","timestamp":1792292974671,"version":"4.4.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T00:00:00Z","timestamp":1477440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Shire HGT"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.bcmd.2016.10.002","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T15:01:52Z","timestamp":1477321312000},"page":"211-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9100-4733","authenticated-orcid":false,"given":"Neal J","family":"Weinreb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah S","family":"Barbouth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2016.10.002_bb0005","series-title":"The Online Metabolic and Molecular Basis of Inherited Metabolic Disease","article-title":"Gaucher disease: Phenotypic and genetic variation","author":"Grabowski","year":"2010"},{"key":"10.1016\/j.bcmd.2016.10.002_bb0010","article-title":"Enzyme replacement and substrate reduction therapy for Gaucher disease","volume":"3","author":"Shemesh","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10.1016\/j.bcmd.2016.10.002_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17071065","article-title":"Less is more: substrate reduction therapy for lysosomal storage disorders","volume":"17","author":"Coutinho","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bcmd.2016.10.002_bb0020","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000057","article-title":"Clinical course and prognosis in patients with Gaucher disease and parkinsonism","volume":"2","author":"Lopez","year":"2016","journal-title":"Neurol. Genet."},{"issue":"1","key":"10.1016\/j.bcmd.2016.10.002_bb0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bcmd.2010.10.006","article-title":"The incidence of parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry","volume":"46","author":"Rosenbloom","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.bcmd.2016.10.002_bb0030","first-page":"S25","article-title":"Gaucher disease and comorbidities: B-cell malignancy and parkinsonism","volume":"90","author":"Cox","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.002_bb0035","doi-asserted-by":"crossref","first-page":"150450","DOI":"10.1155\/2011\/150450","article-title":"Gaucher disease and cancer: concept and controversy","volume":"2011","author":"Choy","year":"2011","journal-title":"Int. J. Cell Biol."},{"issue":"21","key":"10.1016\/j.bcmd.2016.10.002_bb0040","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2016.10.002_bb0045","first-page":"177","article-title":"The pathology of Gaucher disease","volume":"95","author":"Lee","year":"1982","journal-title":"Prog. Clin. Biol. Res."},{"issue":"3","key":"10.1016\/j.bcmd.2016.10.002_bb0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1615\/CritRevOncog.2013005921","article-title":"Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher disease who were never treated with enzyme replacement therapy","volume":"18","author":"Weinreb","year":"2013","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.bcmd.2016.10.002_bb0055","series-title":"75Years of Mortality in the United States","author":"Hoyert","year":"1935"},{"key":"10.1016\/j.bcmd.2016.10.002_bb0060","series-title":"Epidemiology in Medicine","first-page":"85","year":"1987"},{"issue":"3","key":"10.1016\/j.bcmd.2016.10.002_bb0065","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","article-title":"Long-term clinical outcomes in type 1 Gaucher disease following 10years of imiglucerase treatment","volume":"36","author":"Weinreb","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"issue":"7","key":"10.1016\/j.bcmd.2016.10.002_bb0070","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ajh.24040","article-title":"Seven-year safety and efficacy with velaglucerase alfa for treatment-na\u00efve adult patients with type 1 Gaucher disease","volume":"90","author":"Zimran","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.bcmd.2016.10.002_bb0075","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2015.05.012","article-title":"Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 na\u00efve to enzyme replacement therapy or previously treated with imiglucerase","volume":"117","author":"Smith","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2016.10.002_bb0080","article-title":"Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-na\u00efve patients with Gaucher disease","author":"Zimran","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"issue":"2","key":"10.1016\/j.bcmd.2016.10.002_bb0085","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bcmd.2013.04.005","article-title":"Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study","volume":"51","author":"Kuter","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"issue":"4","key":"10.1016\/j.bcmd.2016.10.002_bb0090","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bcmd.2014.04.002","article-title":"Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4years of treatment","volume":"53","author":"Lukina","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.002_bb0095","first-page":"17","article-title":"Clinical response to eliglustat in treatment-na\u00efve patients with Gaucher disease type 1: post-hoc comparison to imiglucerase-treated patients enrolled in the international collaborative Gaucher group Gaucher registry","volume":"8","author":"Ibrahim","year":"2016","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"2","key":"10.1016\/j.bcmd.2016.10.002_bb0100","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11136-004-0794-y","article-title":"Spanish group on Gaucher disease. Quality of life related to type 1 Gaucher disease: Spanish experience","volume":"14","author":"Giraldo","year":"2005","journal-title":"Qual. Life Res."},{"issue":"6","key":"10.1016\/j.bcmd.2016.10.002_bb0105","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1399-0004.2007.00811.x","article-title":"Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease","volume":"71","author":"Weinreb","year":"2007","journal-title":"Clin. Genet."},{"key":"10.1016\/j.bcmd.2016.10.002_bb0110","first-page":"31","article-title":"Quality of life of Brazilian patients with Gaucher disease and fabry disease","volume":"7","author":"Oliveira","year":"2013","journal-title":"JIMD Rep."},{"issue":"1","key":"10.1016\/j.bcmd.2016.10.002_bb0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bcmd.2015.10.001","article-title":"Patients with type 1 Gaucher disease in Spain: a cross-sectional evaluation of health status","volume":"56","author":"Giraldo","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"issue":"1","key":"10.1016\/j.bcmd.2016.10.002_bb0120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13023-016-0435-x","article-title":"Rethinking fatigue in Gaucher disease","volume":"11","author":"Zion","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"issue":"4","key":"10.1016\/j.bcmd.2016.10.002_bb0125","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/jog.12254","article-title":"Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease","volume":"40","author":"Elstein","year":"2014","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.bcmd.2016.10.002_bb0130","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13023-014-0112-x","article-title":"Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications","volume":"9","author":"van Dussen","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"issue":"7","key":"10.1016\/j.bcmd.2016.10.002_bb0135","doi-asserted-by":"crossref","first-page":"A672","DOI":"10.1016\/j.jval.2015.09.1980","article-title":"Health state utilities for Gaucher disease type 1","volume":"18","author":"Ganz","year":"2015","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.bcmd.2016.10.002_bb0140","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1002\/ajmg.a.35624","article-title":"Death rates in the U.S. due to Krabbe disease and related leukodystrophy and lysosomal storage diseases","volume":"158A","author":"Barczykowski","year":"2012","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.bcmd.2016.10.002_bb0145","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1182\/blood.V3.11.1221.1221","article-title":"Adult Gaucher's disease, with special reference to the variations in its clinical course and the value of sternal puncture as an aid to its diagnosis","volume":"3","author":"Groen","year":"1948","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcmd.2016.10.002_bb0150","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7326\/0003-4819-40-3-481","article-title":"Gaucher's disease in 29 cases: hematologic complications and effect of splenectomy","volume":"40","author":"Medoff","year":"1954","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.bcmd.2016.10.002_bb0155","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1161\/01.CIR.35.4.783","article-title":"Gaucher's disease of the lung causing severe pulmonary hypertension with associated acute recurrent pericarditis","volume":"35","author":"Roberts","year":"1967","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.bcmd.2016.10.002_bb0160","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/0002-9343(78)90832-X","article-title":"Unusual cardiac, renal and pulmonary involvement in Gaucher's disease. Interstitial glucocerebroside accumulation, pulmonary hypertension and fatal bone marrow embolization","volume":"65","author":"Smith","year":"1978","journal-title":"Am. J. Med."},{"issue":"1","key":"10.1016\/j.bcmd.2016.10.002_bb0165","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00043426-199021000-00014","article-title":"Pulmonary hypertension and Gaucher's disease: logical association or mere coincidence?","volume":"12","author":"Theise","year":"1990","journal-title":"Am. J. Pediatr. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bcmd.2016.10.002_bb0170","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9610(91)90363-I","article-title":"A 27-year experience with splenectomy for Gaucher's disease","volume":"161","author":"Fleshner","year":"1991","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.bcmd.2016.10.002_bb0175","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.7326\/0003-4819-42-6-1321","article-title":"Gaucher's disease with ascites: a case report with autopsy findings","volume":"42","author":"Morrison","year":"1955","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcmd.2016.10.002_bb0180","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0002-9343(64)90220-7","article-title":"Gaucher's disease (with elevated serum acid phosphatase level) masquerading as cirrhosis of the liver","volume":"37","author":"Tyson","year":"1964","journal-title":"Am. J. Med."},{"issue":"5","key":"10.1016\/j.bcmd.2016.10.002_bb0185","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0022-3476(75)80297-6","article-title":"Combined portal and vena caval hypertension in Gaucher disease: the value of preoperative venography","volume":"87","author":"Fellows","year":"1975","journal-title":"J. Pediatr."},{"issue":"1","key":"10.1016\/j.bcmd.2016.10.002_bb0190","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/0016-5085(81)90202-X","article-title":"LIver abnormalities in patients with Gaucher's disease. LIver abnormalities in patients with Gaucher's disease","volume":"80","author":"James","year":"1981","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcmd.2016.10.002_bb0195","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1750-1172-7-77","article-title":"The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients","volume":"7","author":"Stirnemann","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bcmd.2016.10.002_bb0200","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1750-1172-7-17","article-title":"Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula","volume":"7","author":"Giraldo","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"issue":"12","key":"10.1016\/j.bcmd.2016.10.002_bb0205","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/ajh.21305","article-title":"Life expectancy in Gaucher disease type 1","volume":"83","author":"Weinreb","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.002_bb0210","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bcmd.2016.02.003","article-title":"Persistent immune alterations and comorbidities in splenectomized patients with Gaucher disease","volume":"59","author":"S\u00f8nder","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"issue":"1","key":"10.1016\/j.bcmd.2016.10.002_bb0215","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.atherosclerosis.2008.08.027","article-title":"Low HDL cholesterol levels in type I Gaucher disease do not lead to increased risk of cardiovascular disease","volume":"204","author":"de Fost","year":"2009","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.bcmd.2016.10.002_bb0220","first-page":"428","article-title":"Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. Blood cells Mol. Dis","volume":"40","author":"Langeveld","year":"2008"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107997961630208X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107997961630208X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:34:41Z","timestamp":1761050081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107997961630208X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":44,"alternative-id":["S107997961630208X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.002","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}